Journal article
Increased risk of cognitive impairment in patients with diabetes is associated with metformin
EM Moore, AG Mander, D Ames, MA Kotowicz, RP Carne, H Brodaty, M Woodward, K Boundy, KA Ellis, AI Bush, NG Faux, R Martins, C Szoeke, C Rowe, DA Watters
Diabetes Care | Published : 2013
DOI: 10.2337/dc13-0229
Abstract
OBJECTIVE To investigate the associations of metformin, serum vitamin B12, calciumsupplements, and cognitive impairment in patients with diabetes. RESEARCH DESIGN AND METHODSdParticipants were recruited from the Primary Research in Memory (PRIME) clinics study, the Australian Imaging, Biomarkers and Lifestyle (AIBL) study of aging, and the Barwon region of southeastern Australia. Patients with Alzheimer disease (AD) (n = 480) or mild cognitive impairment (n = 187) and those who were cognitively intact (n = 687) were included; patients with stroke or with neurodegenerative diseases other than AD were excluded. Subgroup analyses were performed for participants who had either type 2 diabetes (n..
View full abstractRelated Projects (1)
Grants
Funding Acknowledgements
The PRIME study was funded by Janssen Australia. This study received support from the National Health and Medical Research Council via the Dementia Collaborative Research Centres program (DCRC2). The AIBL study currently receives funding from the Science Industry Endowment fund. Pfizer International contributed financial support to assist with analysis of blood samples and to further the AIBL research program. Core funding for the AIBL study was provided by the Commonwealth Scientific and Industrial Research Organisation (CSIRO), which was supplemented by in-kind contributions from the study partners: The University of Melbourne, Neurosciences Australia Ltd., Edith Cowan University, Mental Health Research Institute, Alzheimer's Australia, National Ageing Research Institute, Austin Health, University of Western Australia, CogState Ltd., Macquarie University, Hollywood Private Hospital, and Sir Charles Gardner Hospital. AIBL is a shareholder in Cogstate Ltd., Prana Biotechnology Ltd., Mesoblast Pty Ltd., and Eucalyptus Pty Ltd. A.I.B. is a former consultant for Prana Biotechnology Ltd., has received speaker fees from Amgen, and is supported by an Australia Fellowship from the National Health and Medical Research Council (NHMRC). N.G.F. is supported by an NHMRC training fellowship. C.S. is supported in part by a research fellowship funded by Alzheimer's Australia. No other potential conflicts of interest relevant to this article were reported.